Key result
Pericardiocentesis and anti-tubercular therapy yield 1-month recovery in a child with TB pericardial effusion and SARS-CoV-2.
Why the study?
Tuberculous pericardial effusion is a rare, severe manifestation of pediatric TB that may be further complicated by concurrent viral infections such as SARS-CoV-2, presenting diagnostic and management challenges.
Case Report (n=1)
No
Early diagnosis and timely intervention with pericardiocentesis and medical therapy can lead to favorable outcomes in pediatric tuberculous pericardial effusion with concurrent SARS-CoV-2 infection.
Supports timely multimodality therapy in similar cases; hypothesis-generating for pediatric tuberculous pericardial effusion with SARS-CoV-2.
Tuberculosis (TB) continues to be a major cause of morbidity and mortality in children, especially in the endemic regions. Tuberculous pericardial effusion is a rare but severe extrapulmonary manifestation and may be further complicated by concurrent viral infections such as SARS-CoV-2. To describe a rare case of tuberculous pericardial effusion with concurrent SARS-CoV-2 infection in an undernourished child and to discuss the diagnostic challenges and clinical management. A single-center, descriptive case report from a tertiary care hospital. A 9-year-old underweight, malnourished, unvaccinated male child presenting with acute respiratory distress was evaluated clinically and with imaging. Pericardial fluid analysis, Mantoux test, Cartridge-based Nucleic Acid Amplification Test (CBNAAT), and SARS-CoV-2 RT-PCR were performed. Therapeutic pericardiocentesis and anti-tubercular treatment were administered. Investigations revealed a large pericardial effusion with early tamponade physiology. Pericardial fluid showed a lymphocytic exudate with elevated adenosine deaminase. Mantoux test was positive, supporting a diagnosis of tubercular pericarditis despite negative CBNAAT. Concurrent SARS-CoV-2 infection was confirmed on RT-PCR. The child improved significantly following pericardiocentesis, anti-tubercular therapy, corticosteroids, and supportive management, with excellent recovery at 1-month follow-up. Tuberculous pericardial effusion remains a diagnostic challenge in pediatric patients, especially when co-infected with SARS-CoV-2. A high clinical suspicion is essential in TB endemic regions. Early diagnosis and timely intervention can lead to favorable outcomes even in undernourished and unvaccinated children.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2026) conducted a case report in Tuberculous pericardial effusion with concurrent SARS-CoV-2 infection (n=1). Therapeutic pericardiocentesis, anti-tubercular therapy, and corticosteroids was evaluated. Therapeutic pericardiocentesis and anti-tubercular therapy led to excellent recovery at 1-month follow-up in a 9-year-old child with tuberculous pericardial effusion and SARS-CoV-2 infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: